Paul N. Durrington

Paul N. Durrington's AcademicInfluence.com Rankings

Paul N. Durrington

Philosophy

#5277

World Rank

#8035

Historical Rank

Logic

#2583

World Rank

#3595

Historical Rank

philosophy Degrees

Download Badge

Philosophy

Paul N. Durrington's Degrees

Masters Medicine University of Manchester
Doctorate Medicine University of Manchester

Why Is Paul N. Durrington Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Paul N. Durrington's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

[ESC/EAS Guidelines for the management of dyslipidaemias]. (2011) (3612)
Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial (2004) (3586)
ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). (2011) (3071)
ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). (2011) (1103)
Paraoxonase prevents accumulation of lipoperoxides in low‐density lipoprotein (1991) (977)
European guidelines on cardiovascular disease prevention in clinical practice: executive summary. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invit (2007) (911)
Protection of low-density lipoprotein against oxidative modification by high-density lipoprotein associated paraoxonase. (1993) (823)
Risks and benefits of omega 3 fats for mortality, cardiovascular disease, and cancer: systematic review (2006) (726)
LMNA, encoding lamin A/C, is mutated in partial lipodystrophy (2000) (689)
'Ten Commandments' from the 2016 ESC/EAS Guidelines for the management of dyslipidaemias. (2011) (596)
Serum paraoxonase activity in familial hypercholesterolaemia and insulin-dependent diabetes mellitus. (1991) (542)
Association of LDL cholesterol, non-HDL cholesterol, and apolipoprotein B levels with risk of cardiovascular events among patients treated with statins: a meta-analysis. (2012) (532)
Paraoxonase: biochemistry, genetics and relationship to plasma lipoproteins (1996) (490)
Paraoxonase Status in Coronary Heart Disease: Are Activity and Concentration More Important Than Genotype? (2001) (483)
Low Paraoxonase Activity Predicts Coronary Events in the Caerphilly Prospective Study (2003) (437)
Reductions in all-cause, cancer, and coronary mortality in statin-treated patients with heterozygous familial hypercholesterolaemia: a prospective registry study (2008) (427)
Serum paraoxonase activity, concentration, and phenotype distribution in diabetes mellitus and its relationship to serum lipids and lipoproteins. (1995) (423)
Effect of the human serum paraoxonase 55 and 192 genetic polymorphisms on the protection by high density lipoprotein against low density lipoprotein oxidative modification (1998) (389)
Efficacy and safety of statin therapy in older people: a meta-analysis of individual participant data from 28 randomised controlled trials (2019) (377)
Randomised controlled trial evaluating cardiovascular screening and intervention in general practice: principal results of British family heart study (1994) (373)
HDL, its enzymes and its potential to influence lipid peroxidation (1995) (340)
The role of high-density lipoprotein and lipid-soluble antioxidant vitamins in inhibiting low-density lipoprotein oxidation. (1993) (330)
Serum paraoxonase after myocardial infarction. (1999) (322)
Postreceptor insulin resistance contributes to human dyslipidemia and hepatic steatosis. (2009) (297)
Systemic Lupus Erythematosus: An Independent Risk Factor for Endothelial Dysfunction in Women (2004) (294)
Serum paraoxonase (PON1) 55 and 192 polymorphism and paraoxonase activity and concentration in non-insulin dependent diabetes mellitus. (1998) (281)
Omega 3 fatty acids for prevention and treatment of cardiovascular disease. (2004) (281)
Impact of migration on coronary heart disease risk factors: comparison of Gujaratis in Britain and their contemporaries in villages of origin in India. (2006) (270)
APOLIPOPROTEINS (a), AI, AND B AND PARENTAL HISTORY IN MEN WITH EARLY ONSET ISCHAEMIC HEART DISEASE (1988) (266)
Genetic causes of familial hypercholesterolaemia in patients in the UK: relation to plasma lipid levels and coronary heart disease risk (2006) (262)
An omega-3 polyunsaturated fatty acid concentrate administered for one year decreased triglycerides in simvastatin treated patients with coronary heart disease and persisting hypertriglyceridaemia (2001) (259)
Effects of high-dose modified-release nicotinic acid on atherosclerosis and vascular function: a randomized, placebo-controlled, magnetic resonance imaging study. (2009) (242)
Effects of atorvastatin on kidney outcomes and cardiovascular disease in patients with diabetes: an analysis from the Collaborative Atorvastatin Diabetes Study (CARDS). (2009) (236)
Effect of the molecular polymorphisms of human paraoxonase (PON1) on the rate of hydrolysis of paraoxon (1997) (220)
Pharmacogenetic meta-analysis of genome-wide association studies of LDL cholesterol response to statins (2014) (207)
How high-density lipoprotein protects against the effects of lipid peroxidation (2000) (207)
Sequencing of the reannotated LMNB2 gene reveals novel mutations in patients with acquired partial lipodystrophy. (2006) (200)
Effects of insulin and glucose on very low density lipoprotein triglyceride secretion by cultured rat hepatocytes. (1982) (189)
Alloenzymes of paraoxonase and effectiveness of high-density lipoproteins in protecting low-density lipoprotein against lipid peroxidation (1997) (185)
Ezetimibe monotherapy for cholesterol lowering in 2,722 people: systematic review and meta‐analysis of randomized controlled trials (2009) (180)
Levels and Changes of HDL Cholesterol and Apolipoprotein A-I in Relation to Risk of Cardiovascular Events Among Statin-Treated Patients: A Meta-Analysis (2013) (174)
Paraoxonase and coronary heart disease. (1998) (174)
Prevention of cardiovascular disease in systemic lupus erythematosus--proposed guidelines for risk factor management. (2004) (171)
Hypercholesterolaemia and its management (2008) (164)
Effects of two different fibric acid derivatives on lipoproteins, cholesteryl ester transfer, fibrinogen, plasminogen activator inhibitor and paraoxonase activity in type IIb hyperlipoproteinaemia. (1998) (152)
Total Soluble and Endogenous Secretory Receptor for Advanced Glycation End Products as Predictive Biomarkers of Coronary Heart Disease Risk in Patients With Type 2 Diabetes (2011) (146)
The Role of Paraoxonase 1 Activity in Cardiovascular Disease (2004) (145)
Hyperinsulinemia, insulin resistance, and circulating oxidized low density lipoprotein in women with systemic lupus erythematosus. (2006) (139)
Quantification of human serum paraoxonase by enzyme-linked immunoassay: population differences in protein concentrations. (1994) (135)
Influence of proteinuria on vascular disease, blood pressure, and lipoproteins in insulin dependent diabetes mellitus. (1987) (132)
Strategies for reducing coronary heart disease and desirable limits for blood lipid concentrations: guidelines of the British Hyperlipidaemia Association. (1987) (132)
Management of hyperlipidaemia: guidelines of the British Hyperlipidaemia Association. (1993) (128)
Paraoxonase (PON1) polymorphisms in farmers attributing ill health to sheep dip (2002) (126)
Serum apolipoproteins AI and B and lipoproteins in middle aged men with and without previous myocardial infarction. (1986) (121)
Variation in paraoxonase-1 activity and atherosclerosis (2009) (119)
The paraoxonase gene family and coronary heart disease (2002) (118)
A gene variant near ATM is significantly associated with metformin treatment response in type 2 diabetes: a replication and meta-analysis of five cohorts (2012) (117)
Paraoxonase 1 activity, concentration and genotype in cardiovascular disease (2004) (116)
Rapid screening for specific mutations in patients with a clinical diagnosis of familial hypercholesterolaemia. (1991) (112)
Rosuvastatin and fenofibrate alone and in combination in type 2 diabetes patients with combined hyperlipidaemia. (2004) (106)
Lipolysis of triglyceride-rich lipoproteins activates coagulant factor XII: a study in familial lipoprotein-lipase deficiency. (1992) (105)
Serum lipoprotein(a) in patients heterozygous for familial hypercholesterolemia, their relatives, and unrelated control populations. (1991) (104)
Antioxidant properties of HDL (2015) (102)
LIPOPROTEIN ABNORMALITIES IN INSULIN-DEPENDENT DIABETES MELLITUS (1986) (99)
Established and emerging coronary risk factors in patients with heterozygous familial hypercholesterolaemia (2004) (98)
EFFECT OF PECTIN ON SERUM LIPIDS AND LIPOPROTEINS, WHOLE-GUT TRANSIT-TIME, AND STOOL WEIGHT (1976) (97)
Glycation of LDL in non-diabetic people: Small dense LDL is preferentially glycated both in vivo and in vitro. (2009) (95)
Non-enzymatic glycation of apolipoprotein B in the sera of diabetic and non-diabetic subjects. (1992) (94)
Relationship between serum butyrylcholinesterase activity, hypertriglyceridaemia and insulin sensitivity in diabetes mellitus. (1993) (94)
Human cholesterol metabolism and therapeutic molecules (2007) (92)
Cord blood lipoproteins and prenatal influences (2005) (90)
Phenotype-dependent and -independent actions of rosuvastatin on atherogenic lipoprotein subfractions in hyperlipidaemia. (2003) (89)
Hyperlipidaemia : diagnosis and management (1995) (89)
Paraoxonase activity is reduced by a pro-atherosclerotic diet in rabbits. (2000) (88)
Glycation as an atherogenic modification of LDL (2008) (87)
Cholesterol, not just cardiovascular risk, is important in deciding who should receive statin treatment. (2015) (87)
Dyslipidaemia (2003) (87)
Targets of statin therapy: LDL cholesterol, non-HDL cholesterol, and apolipoprotein B in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS). (2009) (85)
Analysis of Efficacy and Safety in Patients Aged 65–75 Years at Randomization (2006) (84)
Susceptibility of LDL and its subfractions to glycation (2011) (84)
Paraoxonase and susceptibility to organophosphorus poisoning in farmers dipping sheep. (2003) (83)
The effect of atorvastatin on serum lipids, lipoproteins and NMR spectroscopy defined lipoprotein subclasses in type 2 diabetic patients with ischaemic heart disease. (2003) (83)
HDL functionality (2012) (82)
Polymorphisms of paraoxonase genes and low-density lipoprotein lipid peroxidation (1999) (81)
Semiautomated method for determination of serum paraoxonase activity using paraoxon as substrate. (2006) (81)
Investigation of lipid transfer in human serum leading to the development of an isotopic method for the determination of endogenous cholesterol esterification and transfer. (1990) (81)
A comparison of methods for the immunoassay of serum apolipoprotein B in man. (1976) (79)
Triglycerides are more important in atherosclerosis than epidemiology has suggested. (1998) (74)
Increased transfer of cholesteryl esters from high density lipoproteins to low density and very low density lipoproteins in patients with angiographic evidence of coronary artery disease. (1993) (74)
Colesevelam added to combination therapy with a statin and ezetimibe in patients with familial hypercholesterolemia: a 12-week, multicenter, randomized, double-blind, controlled trial. (2010) (74)
Alstrom syndrome (OMIM 203800): a case report and literature review (2007) (73)
LADA and CARDS: A Prospective Study of Clinical Outcome in Established Adult-Onset Autoimmune Diabetes (2014) (72)
Evidence-based goals in LDL-C reduction (2017) (70)
Genome-wide association study of genetic determinants of LDL- c response to atorvastatin therapy: importance of Lp(a) (2012) (68)
Human cholesterol metabolism and therapeutic molecules. (2008) (67)
Is paraoxonase related to atherosclerosis. (1993) (67)
Serum esterase activities and hyperlipidaemia in the streptozotocin-diabetic rat. (1990) (67)
An investigation of the role of lecithin:cholesterol acyltransferase and triglyceride-rich lipoproteins in the metabolism of pre-beta high density lipoproteins. (1991) (66)
Coronary heart disease mortality in treated familial hypercholesterolaemia: Update of the UK Simon Broome FH register (2018) (66)
Placebo‐controlled Trial of the Effects of Guar Gum and Metformin on Fasting Blood Glucose and Serum Lipids in Obese, Type 2 Diabetic Patients (1990) (66)
Hypertriglyceridemia and hyperuricemia: effects of two fibric acid derivatives (bezafibrate and fenofibrate) in a double-blind, placebo-controlled trial. (1988) (65)
Effect of organophosphate intoxication on human serum paraoxonase (2002) (63)
Fetal and maternal lipoprotein metabolism in human pregnancy. (1995) (63)
Serum and lipoprotein apolipoprotein B levels in normal subjects and patients with hyperlipoproteinaemia. (1978) (62)
Lipoprotein (a) and Microvascular Disease in Type 1 (Insulin‐dependent) Diabetes (1991) (60)
Paraoxonase activity and genetic polymorphisms in greenhouse workers with long term pesticide exposure (2003) (60)
Comparison of the risk of fatal coronary heart disease in treated xanthomatous and non-xanthomatous heterozygous familial hypercholesterolaemia: a prospective registry study. (2003) (59)
Lipids and their metabolism (2007) (59)
The hunt for nutritional and pharmacological modulators of paraoxonase. (2002) (59)
Familial hypercholesterolaemia commonly presents with Achilles tenosynovitis (2005) (59)
Serum and urinary high density lipoproteins in glomerular disease with proteinuria. (1986) (58)
A Multicenter, Randomized, Placebo‐Controlled Trial of Atorvastatin for the Primary Prevention of Cardiovascular Events in Patients With Rheumatoid Arthritis (2019) (56)
Serum high density lipoprotein cholesterol in diabetes mellitus: an analysis of factors which influence its concentration. (1980) (56)
Small dense LDL is more susceptible to glycation than more buoyant LDL in Type 2 diabetes. (2013) (56)
Abnormalities of VLDL, IDL, and LDL characterize insulin-dependent diabetes mellitus. (1992) (55)
The effect of a low-cholesterol, high-polyunsaturate diet on serum lipid levels, apolipoprotein B levels and triglyceride fatty acid composition. (1977) (55)
Biological variation in serum lipid concentrations. (1990) (54)
Genome-wide association study of genetic determinants of LDL-c response to atorvastatin therapy: importance of Lp(a) [S] (2012) (54)
Squalene synthase inhibitors : clinical pharmacology and cholesterol-lowering potential. (2007) (54)
Rapid emergence of effect of atorvastatin on cardiovascular outcomes in the Collaborative Atorvastatin Diabetes Study (CARDS) (2005) (53)
Fetal and maternal lipoprotein metabolism in human pregnancy complicated by type I diabetes mellitus. (1998) (50)
Effects of treatment of hypertriglyceridaemia with gemfibrozil on serum lipoproteins and the transfer of cholesteryl ester from high density lipoproteins to low density lipoproteins. (1992) (50)
Vitamin E supplementation increases the resistance of both LDL and HDL to oxidation and increases cholesteryl ester transfer activity. (2000) (49)
Managing hyperlipidaemia in patients with COVID-19 and during its pandemic: An expert panel position statement from HEART UK (2020) (49)
Paraoxonase in Persian Gulf War Veterans (2003) (47)
Presence of paraoxonase in human interstitial fluid (1997) (46)
The effect of high-density lipoproteins on the formation of lipid/protein conjugates during in vitro oxidation of low-density lipoprotein. (2003) (45)
Randomised controlled trial evaluating cardiovascular screening and intervention in general practice: principal results of British family heart study. Family Heart Study Group. (1994) (45)
Serum high density lipoprotein cholesterol subfractions in type I (insulin-dependent) diabetes mellitus. (1982) (44)
Hypercholesterolaemia – practical information for non-specialists (2017) (44)
Cost-effectiveness of primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes: results from the Collaborative Atorvastatin Diabetes Study (CARDS) (2007) (43)
Stroke prediction and stroke prevention with atorvastatin in the Collaborative Atorvastatin Diabetes Study (CARDS) (2007) (43)
Non-coronary heart disease mortality and risk of fatal cancer in patients with treated heterozygous familial hypercholesterolaemia: a prospective registry study. (2005) (42)
Small-dense LDL and LDL glycation in metabolic syndrome and in statin-treated and non-statin-treated type 2 diabetes (2010) (42)
The effects of fatty acids on apolipoprotein B secretion by human hepatoma cells (HEP G2). (2000) (42)
Apolipoprotein E genotyping in Alzheimer's disease. (1996) (41)
The safety and tolerability of atorvastatin 10 mg in the Collaborative Atorvastatin Diabetes Study (CARDS) (2008) (41)
Effect of Roux-en-Y Bariatric Surgery on Lipoproteins, Insulin Resistance, and Systemic and Vascular Inflammation in Obesity and Diabetes (2017) (40)
Effect of Treatment With a Hydroxymethylglutaryl Coenzyme A Reductase Inhibitor on Fasting and Postprandial Plasma Lipoproteins and Cholesteryl Ester Transfer Activity in Patients with NIDDM (1995) (39)
Evolocumab for Treating Primary Hypercholesterolaemia and Mixed Dyslipidaemia: An Evidence Review Group Perspective of a NICE Single Technology Appraisal (2016) (39)
How HDL protects LDL against atherogenic modification: paraoxonase 1 and other dramatis personae (2015) (38)
Improvements in Diabetic Neuropathy and Nephropathy After Bariatric Surgery: a Prospective Cohort Study (2020) (37)
Lipid and lipoprotein disorders. (2010) (37)
Treatment of familial hypercholesterolaemia. United Kingdom lipid clinics study of pravastatin and cholestyramine. (1992) (37)
Serum kidney injury molecule 1 and β2-microglobulin perform as well as larger biomarker panels for prediction of rapid decline in renal function in type 2 diabetes (2018) (37)
Protection Against Nephropathy in Diabetes with Atorvastatin (PANDA): a randomized double‐blind placebo‐controlled trial of high‐ vs. low‐dose atorvastatin 1 (2011) (36)
Ethnic differences in myocardial infarction in patients with hypertension: effects of diabetes mellitus. (2008) (36)
High-density lipoprotein impedes glycation of low-density lipoprotein (2013) (35)
Influence of early diabetic nephropathy on very low density lipoprotein (VLDL), intermediate density lipoprotein (IDL), and low density lipoprotein (LDL) composition. (1991) (35)
Dietary intake and the insulin-like growth factor system: effects of migration in two related populations in India and Britain with markedly different dietary intake (2005) (34)
Can measurement of apolipoprotein B replace the lipid profile in the follow-up of patients with lipoprotein disorders? (2002) (34)
Potential population impact of the UK government strategy for reducing the burden of coronary heart disease in England: comparing primary and secondary prevention strategies (2006) (34)
The assessment of Achilles tendon size in primary hypercholesterolaemia by computed tomography. (1982) (34)
A cross-sectional evaluation of cardiovascular risk factors in coronary heart disease associated with type 1 (insulin-dependent) diabetes mellitus. (1992) (34)
Effect of atorvastatin on glycaemia progression in patients with diabetes: an analysis from the Collaborative Atorvastatin in Diabetes Trial (CARDS) (2015) (33)
Patients’ Understandings and Experiences of Familial Hypercholesterolemia (2008) (33)
Validation of the Friedewald formula for the measurement of low density lipoprotein cholesterol in insulin-dependent diabetes mellitus. (1989) (33)
Apolipoproteins, cardiovascular risk and statin response in type 2 diabetes: the Collaborative Atorvastatin Diabetes Study (CARDS) (2009) (33)
Fluctuations of serum and bile lipid concentrations during the menstrual cycle. (1977) (33)
The prevalence of hyperlipidaemia and related clinical features in insulin-dependent diabetes mellitus. (1989) (32)
Squalene Synthase Inhibitors (2003) (32)
Effect of atorvastatin on C-reactive protein and benefits for cardiovascular disease in patients with type 2 diabetes: analyses from the Collaborative Atorvastatin Diabetes Trial (2015) (32)
Meta-analysis of genome-wide association studies of HDL cholesterol response to statins (2016) (31)
Metabolism of apoB-100-containing lipoproteins in familial hyperchylomicronemia. (1993) (30)
High-density lipoprotein cholesterol: methods and clinical significance. (1982) (30)
American, British and European recommendations for statins in the primary prevention of cardiovascular disease applied to British men studied prospectively (2006) (30)
Coronary heart disease mortality in severe vs. non-severe familial hypercholesterolaemia in the Simon Broome Register (2019) (30)
All-cause and cardiovascular mortality in treated patients with severe hypertriglyceridaemia: A long-term prospective registry study. (2009) (30)
Effects of hormone replacement therapy on insulin-like growth factor (IGF)-I, IGF-II and IGF binding protein (IGFBP)-1 to IGFBP-4: Implications for cardiovascular risk (2005) (29)
Apolipoprotein A5 and hypertriglyceridemia. (2005) (28)
Rosuvastatin: efficacy, safety and clinical effectiveness. (2008) (28)
Treatment of Dyslipoproteinaemia in Diabetes Mellitus (1996) (28)
Are recent statin recommendations to employ fixed doses and abandon targets effective for treatment of hypercholesterolaemia? Investigation based on number needed to treat (2017) (27)
Double-blind, placebo-controlled, cross-over trial of probucol in heterozygous familial hypercholesterolaemia. (1985) (27)
Association of a sequence variant in DAB2IP with coronary heart disease (2011) (27)
Double‐blind Placebo‐controlled Study of the Effects of Bezafibrate on Blood Lipids, Lipoproteins, and Fibrinogen in Hyperlipidaemic Type 1 Diabetes Mellitus (1990) (27)
Progestogens of varying androgenicity and cardiovascular risk factors in postmenopausal women receiving oestrogen replacement therapy (2004) (26)
Clinical Value of Apolipoprotein Measurement (1991) (25)
Apolipoproteins AI and B as therapeutic targets (2006) (25)
THE HUMAN AND ECONOMIC COSTS OF UNDERTREATMENT WITH STATINS (2002) (25)
Adiponectin in umbilical cord blood is inversely related to low-density lipoprotein cholesterol but not ethnicity. (2006) (25)
Suppression of non-esterified fatty acids to treat type A insulin resistance syndrome (1994) (25)
Lipoprotein secretion by the human hepatoma cell line Hep G2: differential rates of accumulation of apolipoprotein B and lipoprotein lipids in tissue culture media in response to albumin, glucose and oleate. (1991) (25)
Florid xanthelasmata (yellow lids) in orbital Wegener's granulomatosis. (1995) (24)
Effect of low-dose cyclosporin on plasma lipoproteins and markers of cholestasis in patients with psoriasis. (1995) (24)
EFFECT OF BRAN ON BLOOD-LIPIDS (1975) (24)
Effect of phenobarbitone on plasma lipids in normal subjects. (1976) (23)
Effect of statin therapy on muscle symptoms: an individual participant data meta-analysis of large-scale, randomised, double-blind trials (2022) (23)
Impairment of high-density lipoprotein resistance to lipid peroxidation and adipose tissue inflammation in obesity complicated by obstructive sleep apnea. (2014) (23)
Apolipoprotein E polymorphism and lipoproteins in insulin-treated diabetes mellitus. (1989) (22)
Effect of Extended-Release Niacin on High-Density Lipoprotein (HDL) Functionality, Lipoprotein Metabolism, and Mediators of Vascular Inflammation in Statin-Treated Patients (2015) (22)
Acute-pancreatitis: a complication of beta-blockade. (1982) (22)
Bariatric surgery leads to an improvement in small nerve fibre damage in subjects with obesity (2021) (22)
Hunter's Diseases of Occupations, Tenth Edition (2010) (21)
Apolipoprotein B100 is a better treatment target than calculated LDL and non-HDL cholesterol in statin-treated patients (2011) (21)
Diabetic dyslipidaemia. (2016) (20)
Triglycerides and small dense low density lipoprotein in the discrimination of coronary heart disease risk in South Asian populations. (2010) (20)
A Comparative Study of Six Commercial Lipoprotein(a) Assays in Seventeen Laboratories within the British Isles (1996) (20)
Does measurement of apolipoproteins add to the clinical diagnosis and management of dyslipidaemias (1993) (20)
Severe insulin resistance, diabetes mellitus, hypertriglyceridemia, and pseudoacromegaly. (1996) (20)
Measurement of plasma small-dense LDL concentration by a simplified ultracentrifugation procedure and immunoassay of apolipoprotein B. (2003) (20)
Cost Effectiveness of Ezetimibe in Patients with Cardiovascular Disease and Statin Intolerance or Contraindications (2008) (20)
A Comparison of Three Methods of Measuring Serum High Density Lipoprotein Cholesterol in Diabetics and Non-Diabetics (1980) (20)
Spontaneous platelet aggregation in whole blood is increased in non-insulin-dependent diabetes mellitus and in female but not male patients with primary dyslipidemia. (1995) (19)
Preventing cardiovascular disease in hypertension: effects of lowering blood pressure and cholesterol. (2002) (19)
Differing predictive relationships between baseline LDL-C, systolic blood pressure, and cardiovascular outcomes. (2016) (19)
Substrate specificity of human serum paraoxonase. (1991) (18)
Hypertriglyceridaemia and abnormalities of triglyceride catabolism persisting after pancreatitis (1986) (17)
Estimated 10‐year cardiovascular risk in a British population: results of a national screening project (2008) (17)
Nonesterified fatty acids as mediators of glucose intolerance in Indian Asian populations. (2005) (17)
Optimising treatment of hyperlipidaemia: Quantitative evaluation of UK, USA and European guidelines taking account of both LDL cholesterol levels and cardiovascular disease risk. (2018) (17)
Clinical, biochemical, and immunohistochemical features of necrobiotic xanthogranulomatosis (2003) (17)
Effects of dydrogesterone and norethisterone, in combination with oestradiol, on lipoproteins and inflammatory markers in postmenopausal women. (2006) (16)
Rigorous detection and vigorous treatment of familial hypercholesterolaemia (2001) (16)
Migration is associated with lower total, but not free testosterone levels in South Asian men (2007) (16)
The effect of bezafibrate on very low density lipoprotein (VLDL), intermediate density lipoprotein (IDL), and low density lipoprotein (LDL) composition in type 1 diabetes associated with hypercholesterolaemia or combined hyperlipidaemia. (1992) (16)
HDL in risk prediction and its direct and indirect involvement in atherogenesis. (2002) (16)
Coronary heart disease mortality in treated familial hypercholesterolaemia: Update of the UK Simon Broome FH register. (2018) (16)
Secondary hyperlipidaemia. (1990) (15)
4 Hyperlipidaemia and renal disease (1990) (15)
Serum lipoprotein (a) in men with proteinuria due to idiopathic membranous nephropathy. (1992) (15)
Bezafibrate Retard in Patients with Insulin‐Dependent Diabetes: Effect on Serum Lipoproteins, Fibrinogen, and Glycemic Control (1990) (15)
Analysis of predicted coronary heart disease risk in England based on Framingham study risk appraisal models published in 1991 and 2000 (2002) (15)
Estimating the health benefits and costs associated with ezetimibe coadministered with statin therapy compared with higher dose statin monotherapy in patients with established cardiovascular disease: results of a Markov model for UK costs using data registries. (2008) (14)
The effect of atorvastatin on serum lipoproteins in acromegaly (2005) (14)
Treatment of mixed hyperlipidaemia using a combination of omega-3 fatty acids and HMG CoA reductase inhibitor (2001) (14)
Adiponectin and lipid profiles compared with insulins in relation to early growth of British South Asian and European children: the Manchester children's growth and vascular health study. (2011) (14)
Lipoprotein (a): gene genie (2014) (14)
Rosuvastatin: efficacy, safety and clinical effectiveness (2008) (13)
GST, CYP and PON1 polymorphisms in farmers attributing ill health to organophosphate-containing sheep dip (2007) (13)
Quantitative evaluation of statin effectiveness versus intolerance and strategies for management of intolerance. (2020) (13)
The importance of considering LDL cholesterol response as well as cardiovascular risk in deciding who can benefit from statin therapy (2014) (13)
Is Insulin Atherogenic? (1992) (12)
Hyperlipidemia. Diagnosis and Management (2007) (12)
Evidence for more intensive cholesterol lowering (2017) (12)
Lipoprotein glycation in atherogenesis (2009) (12)
Hyperlipidaemia and renal disease. (1990) (12)
Evolocumab for Treating Primary Hypercholesterolaemia and Mixed Dyslipidaemia: An Evidence Review Group Perspective of a NICE Single Technology Appraisal (2016) (12)
Body fat distribution in relation to smoking and exogenous hormones in British women (2012) (12)
Bariatric surgery as a model to explore the basis and consequences of the Reaven hypothesis: Small, dense low-density lipoprotein and interleukin-6 (2019) (11)
Paraoxonase gene polymorphism and serum activity in progressive IgA nephropathy. (2006) (11)
1,25 Dihydroxyvitamin D and cancer. (1997) (11)
Increased C‐reactive protein levels in overweight and obese women taking exogenous hormones: the United Kingdom Women’s Heart Study (UKWHS) (2009) (11)
Population impact of stricter adherence to recommendations for pharmacological and lifestyle interventions over one year in patients with coronary heart disease (2005) (11)
Molecular characterization of two patients with severe LCAT deficiency. (2007) (11)
Lipid-lowering drugs: who gets what? (1998) (11)
Implications of 4S evidence on baseline lipid levels (1995) (11)
Indices of Obesity and Cardiovascular Risk Factors in British Women (2008) (11)
A comparison of the effects of low- and high-dose atorvastatin on lipoprotein metabolism and inflammatory cytokines in type 2 diabetes: Results from the Protection Against Nephropathy in Diabetes with Atorvastatin (PANDA) randomized trial. (2017) (11)
Marked differences in the IGF system that are associated with migration in comparable populations of Gujaratis living in Sandwell, UK, and Gujarat, India (2005) (10)
Elevation of skeletal muscle isoform of serum creatine kinase in heterozygous familial hypercholesterolaemia (1990) (10)
An investigation to determine the nutritional adequacy and individuals experience of a very low fat diet used to treat type V hypertriglyceridaemia. (2009) (10)
Predicting major adverse cardiovascular events for secondary prevention: protocol for a systematic review and meta-analysis of risk prediction models (2020) (10)
Sex differences in cardiovascular morbidity associated with familial hypercholesterolaemia: A retrospective cohort study of the UK Simon Broome register linked to national hospital records (2020) (10)
Cholesterol Levels Should Play a More Important Role in Identifying Statin Recipients. (2017) (10)
Change in pancreatic B‐cell function (HOMA‐B) varies in different populations with similar genetic backgrounds but different environments (2007) (9)
A Randomized Cross‐over Study of the Effects of Proinsulin on Lipid Metabolism in Type 2 Diabetes (1991) (9)
Laboratory facilities for investigating lipid disorders in the United Kingdom: results of the British Hyperlipidaemia Association survey. (1992) (9)
Diabetes, hypertension and hyperlipidaemia. (1993) (9)
Statins and Fibrates in the Management of Diabetic Dyslipidaemia (1997) (9)
Dyslipidemia and atherosclerosis: how much more evidence do we need? (1999) (8)
Atorvastatin administration is associated with dose-related changes in IGF bioavailability. (2013) (8)
Does residual insulin secretion (assessed by C-peptide concentration) affect lipid and lipoprotein levels in insulin-dependent diabetes mellitus? (1989) (8)
H.D.L. CHOLESTEROL IN DIABETES MELLITUS (1978) (8)
Costs of aspirin and statins in general practice. (2002) (8)
Work and Psychiatric Disorder (2010) (8)
Apolipoprotein CIII and N-terminal prohormone b-type natriuretic peptide as independent predictors for cardiovascular disease in type 2 diabetes. (2018) (8)
Non-HDL cholesterol should not generally replace LDL cholesterol in the management of hyperlipidaemia. (2019) (7)
The role of abnormalities of lipoproteins and HDL functionality in small fibre dysfunction in people with severe obesity (2021) (7)
The Role of Paraoxonase in Lipid Metabolism (2002) (7)
Acquired low cholesterol: diagnosis and relevance to safety of low LDL therapeutic targets (2018) (6)
Hyperlipidaemia 3Ed: Diagnosis and Management (1989) (6)
Use of the TLX ultracentrifuge for the isolation of different density lipoproteins and effects of freeze/thawing of human plasma before ultracentrifugation (2008) (6)
Frequency of citation and outcome of cholesterol lowering trials. (1992) (6)
Effect of bariatric surgery on plasma levels of oxidised phospholipids, biomarkers of oxidised LDL and lipoprotein(a). (2020) (6)
ESC/EAS Guidelines for the management of dyslipidaemias The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). (2011) (6)
Lipid-lowering drug therapy: more knowledge leads to more problems for composers of guidelines (2000) (6)
Wrong lesson from Finnish trial of cardiovascular disease prevention (1992) (6)
Can we afford to treat hyperlipidaemia as we should? Strategies for rational treatment. (1998) (6)
Effects of insulin and glucagon on the secretion of apolipoprotein B-containing lipoproteins and triacylglycerol synthesis by human hepatoma (Hep G2) cells (1994) (5)
Mo-W14:4 Apolipoproteins as predictors of cardiovascular risk in the collaborative atorvastatin diabetes study (Cards) (2006) (5)
review systematic cardiovascular disease, and cancer: Risks and benefits of omega 3 fats for mortality, (2006) (5)
Proteinuria and severe mixed dyslipidemia associated with a novel APOAV gene mutation. (2010) (5)
An evaluation of the Reflotron for the determination of plasma cholesterol in capillary blood. Effect of operator variability. (1993) (5)
Clinical Management of Children and Young Adults with Heterozygous Familial Hypercholesterolaemia in the UK (2004) (5)
Diabetic dyslipidaemia (2016) (5)
Clinical management of children and young adults with heterozygous familial hypercholesterolaemia in the UK. (2004) (5)
Unintended positive and negative effects of drugs on lipoproteins (2015) (5)
HDL functionality in diabetes mellitus: potential importance of glycation (2012) (5)
The role of hydrostatic pressure in foam cell formation upon exposure of macrophages to LDL and oxidized LDL. (2008) (5)
Familial hypobetalipoproteinemia due to a novel early stop mutation. (2008) (5)
Nonenzymatic glycation of apolipoprotein B in diabetic and non-diabetic subjects (1991) (5)
The robustness of the Roche 2nd generation homogenous HDL cholesterol (PEGME) method: assessment of the effect of serum sample storage for up to 8 years at -80 degrees C. (2007) (5)
Lipoproteins and their metabolism (2007) (5)
Postprandial plasma lipoprotein responses to a mixed meal in subjects with hyperapobetalipoproteinaemia. (1992) (5)
The european society of cardiology and the european atherosclerosis society (ESC/EAS) guidelines on the management of dyslipidemia (2011) (5)
Comprar Hyperlipidemia. Diagnosis and Management | Paul N Durrington | 9780340807811 | Hodder Arnold (2007) (4)
PON1 in Other Diseases (2002) (4)
GLYCATION OF LDL IS AN IMPORTANT ATHEROGENIC MODIFICATION AND OPPOSED BY PARAOXONASE-RICH HDL (2009) (4)
Genome-Wide Association Study of CRP Response to Statin Therapy in Diabetes in the CARDS Trial (2014) (4)
Therapeutic aspects of hyperlipidaemia in diabetes. (1989) (4)
3.P.81 Immunolocalisation of paraoxonase with clusterin and apolipoprotein A1 in the human artery wall (1997) (4)
HDL prevents the formation of aldehyde adducts on apo-B during the oxidation of LDL (2000) (4)
Clinical trials of lipid-lowering medication in diabetes (2003) (4)
Coronary risk factors in people from the Indian subcontinent (1995) (4)
Liver Fat Measured by MR Spectroscopy: Estimate of Imprecision and Relationship with Serum Glycerol, Caeruloplasmin and Non-Esterified Fatty Acids (2016) (4)
Statin policy and target populations: evidence-based or evidence-biased? (2004) (4)
Cholesteryl ester transfer protein (CETP) inhibitors (2012) (3)
Retreat (2002) (3)
POPULATION SCREENING FOR SERUM CHOLESTEROL (1989) (3)
Risk in cardiovascular disease. Joint British societies recommend their computer program for risk calculations. (2000) (3)
Letter: Serum cholesterol and enzyme-inducing agents. (1975) (3)
Calculation of coronary risk in Type II diabetes. (2001) (3)
Borderline hypercholesterolaemia: when to introduce drugs. (1989) (3)
Non-HDL or LDL cholesterol in heterozygous familial hypercholesterolaemia: findings of the Simon Broome Register. (2020) (3)
Ischaemic heart disease and cholesterol. Cholesterol reduction effective in established disease... (1994) (3)
9. Role of HDL in preventing atherogenic modification of LDL (1999) (3)
Normal levels of inflammatory markers in treated patients with familial hypercholesterolaemia: a cross-sectional study (2012) (3)
The National Cholesterol Education Program III scoring system for CHD risk estimation cannot be used with European recommendations (2004) (3)
Isolation of plasma small-dense low-density lipoprotein using a simple air-driven ultracentrifuge and quantification using immunassay of apolipoprotein B (2004) (3)
Facilities for the management of patients with lipid disorders in the United Kingdom: results of the British Hyperlipidaemia Association Survey. (1991) (2)
Changes in inflammation markers, adipose tissue properties, glucose homeostasis and lipoproteins after gastric bypass surgery in morbidly obese patients (2013) (2)
Early results of a cohort study of severe hyperlipidaemia (1989) (2)
Diseases Associated with Physical Agents (2010) (2)
Changes In Serum Triglycerides Are Associated With Improvements In Small Fibre Neuropathy In Obese Persons Following Bariatric Surgery (2019) (2)
What every doctor wants to know about cholesterol: answers to some difficult questions (1992) (2)
Coronary risk factors: value of screening and preventive strategies in general practice. (1990) (2)
Glycated apolipoprotein B decreases after bariatric surgery in people with and without diabetes: A potential contribution to reduction in cardiovascular risk. (2022) (2)
Apolipoproteins, cardiovascular risk and statin response in type 2 diabetes: the Collaborative Atorvastatin Diabetes Study (CARDS) (2008) (2)
A case for lipid‐lowering? (2000) (2)
Can any agreement be reached on cholesterol lowering? (1994) (2)
Fast Facts: Hyperlipidemia (2010) (2)
The Reaven syndrome: An historical perspective (2019) (2)
Family History and Lipoprotein(a) Contribute Independently to Risk Assessment and Clinical Management. (2020) (2)
Lipoprotein Abnormalities in Insulin-Dependent Diabetes Mellitus (IDDM) (1986) (2)
Bariatric Surgery-induced High-density Lipoprotein Functionality Enhancement Is Associated With Reduced Inflammation. (2022) (2)
Metabolism:Editorial comment (1990) (2)
Susceptibility of LDL and HDL from patients with diabetes mellitus to in vitro oxidative modification (1994) (2)
Improvement in small fibre neuropathy and inflammatory biomarkers after bariatric surgery. (2016) (2)
EFFECTS OF OBESITY AND BARIATRIC SURGERY ON HDL FUNCTIONALITY AND MICROVASCULAR COMPLICATIONS OF OBESITY (2016) (2)
The changing face of occupational diseases (2010) (1)
Effect of bariatric surgery on HDL quantity and quality (2016) (1)
Reductions in glycated apolipoprotein B after bariatric surgery are more closely associated with decreases in glycaemic parameters than changes in LDL-C or total apolipoprotein B (2018) (1)
Effect of a New Fish Oil Concentrate (OMACOR) on Plasma Lipids and Lipoproteins in Patients with Hypertriglyceridaemia (1995) (1)
Colesevelam: new alternative or adjunctive treatment to statins (2008) (1)
Comprar Hunter's Diseases Of Occupations | Peter Baxter | 9780340941669 | Hodder Education (2010) (1)
C-reactive Protein and Amyloid A as Predictors of Cardiovascular Events in Type 2 Diabetes in the CARDS Study (2009) (1)
MRC/BHF Heart protection study. Authors' reply (2002) (1)
Serum paraoxonase activity in Type 1 and Type 2 diabetes (1994) (1)
Cost-effectiveness of atorvastatin (10mg) in patients with type 2 diabetes without coronary heart disease: CARDS trial analysis and extrapolation (2005) (1)
Mo-W1:5 Effect of rosuvastatin on remodelling of high-density lipoproteins in atherogenic dyslipidaemias: Role of cholesteryl ester transfer protein (CETP) (2006) (1)
Compositional abnormalities in lipoprotein in insulin-dependent diabetes mellitus (IDDM) by discontinuous gradient ultracentrifugation (DGU) (1989) (1)
Assessment of 2 methods for isolation of high-density lipoprotein (2011) (1)
Cardiovascular disease morbidity is associated with social deprivation in subjects with familial hypercholesterolaemia (FH): a study comparing FH individuals in UK primary care and the UK Simon Broome register linked with secondary care records (2022) (1)
Blood lipids after COVID-19 infection (2023) (1)
Lipid Research Clinics Program (1984) (1)
Serum lipoprotein (a) in heterozygotes for familial hypercholesterolaemia (FH) their relatives and controls (1990) (1)
Circulating Haemoglobin Levels and the Risk of Atherosclerosis in Asian Indian Populations (2015) (1)
Letter: Effect of bran on blood-lipids. (1975) (1)
Comparison of insulin sensitivity in people of Indian origin living in West London and their siblings in India (1994) (1)
Patterns of post-prandial lipaemia in insulin-treated type 2 (non-insulin-dependent) diabetes mellitus and in health (1988) (1)
Concentrations in Men and Women With Familial Hypercholesterolemia , Related and Unrelated , in Unrelated Familial Hypercholesterolemia Probands , in Controls With Normal Serum Lipid Levels , and in Controls With Hypercholesterolemia Not Due to Familial Hypercholesterolemia Variable Norn (2005) (1)
Common hyperlipidaemia: familial combined hyperlipidaemia, hyperapobetalipoproteinaemia and polygenic hypercholesterolaemia (2007) (1)
BHPR research: qualitative1. Complex reasoning determines patients’ perception of outcome following foot surgery in rheumatoid arhtritis (2012) (1)
3SY05-6 Paraoxonase: Biochemistry and contribution to atherosclerosis (2003) (1)
Coronary heart disease mortality in treated familial hypercholesterolaemia : Update of the UK Simon Broome FH register (2018) (1)
Migration Related Differences in Blood Iron Availability Among Resident Compared With Migrant South Asians are Related to Indices of Atherogenesis (2008) (1)
Cholesterol lowering in secondary prevention: Could do better. (2021) (1)
Bariatric surgery enhances reverse cholesterol transport and high density lipoprotein functionality (2018) (1)
Does statin therapy improve short-term clinical outcomes in acute coronary syndromes? (2006) (1)
The future of coronary heart disease prevention. (2007) (1)
Bariatric Surgery Leads to a Reduction in Antibodies to Apolipoprotein A-1: a Prospective Cohort Study (2021) (1)
The importance of considering low-density lipoprotein cholesterol response as well as cardiovascular risk in deciding who can benefit from statin therapy. (2014) (1)
Other non-fibrous mineral dusts (2010) (1)
Preliminary results of a double blind comparison of pravastatin and cholestyramine in familial hypercholesterolaemia (1989) (1)
With statin co-administration, drugs designed to increase HDL have no impact on cardiovascular outcomes (2014) (1)
The importance of considering LDL-C response as well as cardiovascular risk in deciding who can benefit from statin therapy. (2014) (1)
Lipoprotein composition & reverse cholesterol transport in the fasting & postprandial state in patients treated with gemfibrozil (1990) (1)
(5) High paraoxonase-1 hdl is more effective than low paraoxonase-1 hdl in impeding ldl oxidation in vitro (2012) (1)
Susceptibility of low and high density lipoproteins from subjects with diabetes to in vitro oxidative modification (1995) (1)
Serum insulin, glucose and non-esterified fatty acid response to a standardized mixed meal in patients with primary hypertriglyceridemia treated with gemfibrozil (1994) (1)
Causes of Diabetes - Genetic and Environmental Factors (1994) (0)
Characteristics and cardiovascular disease morbidity of men and women with familial hypercholesterolaemia (FH): a cohort study using data from the UK Simon Broome register linked with secondary care records (2020) (0)
The occupational history (2010) (0)
High-dose atorvastatin reduces apolipoprotein E concentration significantly and this is influenced by the apolipoprotein E genotype (2011) (0)
Residual adverse vascular risk and oxidative stress in treated adult panhypopituitarism (2008) (0)
Serum High-Density Lipoprotein (HDL) Sub-Fractions in Non-Minimal Change Nephrotic Syndrome (NMCNS) (1984) (0)
Abstract: 1513 STATIN THERAPY IN DIABETES (2009) (0)
Hormone replacement treatment (HRT) increases circulating insulin-like growth factor binding protein-4 concentration (2003) (0)
Glycation as an atherogenic modification of lipoproteins, and the contribution of copper (2015) (0)
Extended release niacin lowers mediators of vascular inflammation but does not improve in vitro HDL antioxidant function in statin treated dyslipidemic patients (2013) (0)
Abstract: 577 COLESEVELAM ADDED TO STABLE COMBINATION OF STATIN AND EZETIMIBE IN PATIENTS WITH FAMILIAL HYPERCHOLESTEROLEMIA; THE TRIPLE TRIAL (2009) (0)
Transfer of cholesteryl esters from HDL to VLDL and LDL (CET) is increased in patients with type 2 diabetes mellitus (DM) (1994) (0)
Systemic Lupus Erythematosus (2014) (0)
Lipid-modifying therapy (2007) (0)
SLE and antiphospholipid syndrome 168. Dyslipidaemia, Hyperhomocysteinaemia and Antiphospholipid Antibodies as Risk Factors of Thrombotic Complications in Patients with Systemic Lupus Erythematosus (2011) (0)
Silica and silica-related diseases (2010) (0)
Anaemia and iron metabolism as risk factors for glucose intolerance amongst men and women originating from the Indian subcontinent (2014) (0)
A meta-analysis of the effect of intensive cholesterol reduction on numbers needed to treat to prevent cardiovascular events in 75439 participants in 10 randomised controlled clinical trials (2017) (0)
The effects of saturated fatty acids on apolipoprotein B secretion by human hepatoma (Hep G2) cells (1993) (0)
Other Chemical Exposures (2010) (0)
Edinburgh Research Explorer Effect of atorvastatin on glycaemia progression in patients with diabetes (2018) (0)
Management ofhyperlipidaemia: guidelines oftheBritish Hyperlipidaemia Association (1993) (0)
Abstract 984: Change in Lp-PLA2 With Risk Change on Statin Therapy in the Collaborative Atorvastatin Diabetes Study (CARDS) (2009) (0)
Other Effects of Workplace Exposures (2010) (0)
Apolipoprotein E in Healthy Volunteers (2012) (0)
4P-0955 Inhibition of oxidised-LDL induced endothelial cell MCP-1 production by paraoxonase (PON1) (2003) (0)
Improved glycaemic control and insulin sensitivity during sustained suppression of serum non-esterified fatty acids (NEFA) in type 2 diabetic patients (1995) (0)
The prevalence of hypercholesterolaemia (hc) & related clinical features in insulin dependent diabetes mellitus (IDDM) (1987) (0)
C reactive protein and its relation to CHD risk factors for a population of Indian migrants living in the UK (2001) (0)
A comparison of low and high dose atorvastatin on lipoproteins and inflammatory cytokines: the protection against nephropathy in diabetes with atorvastatin (panda) trial (2015) (0)
Introduction (1991) (0)
Lipids and inflammatory parameters in patients with early inflammatory arthritis. (2012) (0)
Diet and Heart Disease: A Round Table of Facts (1994) (0)
Protection against accumulation of peroxides in LDL by HDL and its associated enzyme, paraoxonase (1994) (0)
Diseases Associated with Chemical Agents (2010) (0)
Prevention of Macrovascular Disease: Absolute Proof or Absolute Risk? (1995) (0)
Prevention of CHD: implications of the Framingham study coronary risk appraisal models published in 1991 and 2000 [Conference presentation] (2002) (0)
1st Central European Congress on Obesity: From Nutrition to Metabolic Syndrome (2008) (0)
Genetics of lipoprotein disorders and coronary atheroma (2007) (0)
W09.199 Small dense LDL is more common amongst rural Indians compared to migrant contemporaries: Populations susceptible to insulin resistance and metabolic syndrome (2004) (0)
Serum lipid and lipoprotein concentrations in health and in disease (2007) (0)
Apolipoprotein (a) (apo(a)) in middle-aged men with and without ischaemic heart disease (IHD) (1988) (0)
APOLIPOPROTEIN B PROVIDES A MORE CONSISTENT GOAL OF STATIN TREATMENT THAN LDL-C AND NON-HDL-C (2009) (0)
W06.169 HDL does not inhibit MCP-1 secretion by endothelial cells, in response to incubation with TNF$alpha; (2004) (0)
Extent and Attribution of Occupational Disease (2010) (0)
Coronary heart disease mortality in severe and non-severe familial hypercholesterolaemia: data from the uk simon broome fh register (2018) (0)
Abstract: 1011 LDL GLYCATION, A POTENTIALLY ATHEROGENIC MODIFICATION IN NON-DIABETIC AND DIABETIC PEOPLE (2009) (0)
Severe Hypertriglyceridaemia and Chylomicronaemia Syndrome—Causes, Clinical Presentation, and Therapeutic Options (2023) (0)
P287 LONGITUDINAL ASSESSMENT OF DYSLIPIDEMIA AMONG PATIENTS TREATED WITH LIPID MODIFYING THERAPY IN UK CLINICAL PRACTICE (2010) (0)
Occupation and Transmissible Diseases (2010) (0)
Isolation of plasma small-dense LDL using a simple air-driven ultracentrifuge and quantification using immunoassay of apolipoprotein B, (2004) (0)
Coronary prevention in current diabetic practice, on 16 November 1990 at Bolton, Lancs. (1991) (0)
Factors Affecting Serum Paraoxonase 1 Activity in Migrant and Resident Gujarati South Asians (2014) (0)
P Vascular Effects of Nicotinic Acid Effects of High-Dose Modified-Release Nicotinic Acid on Atherosclerosis and Vascular Function A Randomized , Placebo-Controlled , Magnetic Resonance Imaging Study (0)
Serum lipids, plasma lipoproteins reverse cholesterol transport in obese subjects during severe calorie restriction (1994) (0)
The Year in Dyslipidaemia 2004 (2004) (0)
Effect of Antioxidant Supplimentation on the Susceptibility of Low Density Lipoprotein (Ldl) to Oxidation (1994) (0)
The effect of insulin, glucagon and oleic acid on the particle size and composition of apolipoprotein B-containing lipoproteins secreted by HEP G2 cells (1995) (0)
A comparative study of the value of lipid and apolipoprotein measurements in evaluating risk of coronary artery disease in two study groups (1993) (0)
Reduction in cardiovascular disease morbidity of men and women with familial hypercholesterolaemia (FH) associated with availability of high intensity statins: A cohort study using data from the UK Simon Broome Register linked with secondary care records (2021) (0)
8) Distribution and concentration of apolipoprotein e in healthy volunteers (2012) (0)
Migration to the UK results in significantly lower testosterone levels in South Asian men (2006) (0)
Serum butyrylcholinesterase activity (BChe) hypertriglyceridaemia and insulin resistance in diabetes mellitus (1993) (0)
IS SMALL DENSE LDL A MORE IMPORTANT DETERMINANT OF THE PLASMA GLYCATED LDL IN TYPE 2 DIABETES THAN GLYCAEMIC CONTROL (2009) (0)
Coronary prevention: Multifactorial approach in clinical practice (1995) (0)
Type III hyperlipoproteinaemia (2007) (0)
(6) In statin treated patients, high hdl paraoxonase-1 activity protects ldl and hdl from oxidation in vitro (2012) (0)
P209 GLYCATED LDL STIMULATE FOAM CELL FORMATION IN VITRO AND LDL GLYCATION IS OPPOSED BY PARAOXONASE-RICH HDL (2010) (0)
3.P.2 The effect of vitamin E on lipoprotein oxidation and cholesteryl ester transfer (1997) (0)
Bioterrorism and Biotechnology (2010) (0)
Vascular risk factors in coronary heart disease (CHD) associated with type 1 diabetes mellitus (1991) (0)
Serum lipids & apolipoproteins in South Asians living in the UK and their siblings in India (1993) (0)
Dietary intake and the IGF-system: a study in two related populations with a markedly different dietary intake (2004) (0)
Comparison of serum lipids and apolipoproteins in people from the Indian subcontinent living in West London and their siblings in India (1994) (0)
Effect of Roux-en-Y bariatric surgery on lipoproteins, insulin resistance, and systemic and vascular inflammation in obese patients with and without diabetes (2017) (0)
Esterification and transfer of cholesterol in the postprandial state (1988) (0)
258 Lipid Profile in Patients With Inflammatory Polyarthritis Prior to Therapy (2011) (0)
NICE guidance for identification and treatment of familial hypercholesterolaemia: Commentary 2 (2008) (0)
Effect of bariatric surgery on apolipoproteine concentration and distribution (2015) (0)
Paraoxonase polymorphisms and coronary heart disease. Authors' reply (2004) (0)
4.P.69 Serum platelet activating factor-acetylhydrolase (PAF-AH) activity in diabetes (1997) (0)
Back and Spinal Pain (2010) (0)
Cardiovascular disease incidence in 21 years follow-up in severe and non-severe familial hypercholesterolaemia (FH) : Data from the UK Simon Broome FH register (2020) (0)
Clinical aspects of hyperlipidaemia. (1984) (0)
Effect of pravastatin on the transfer of cholesteryl esters from HDL to VLDL and LDL (CET) in the fasting and postprandial state in patients with type 2 diabetes mellitus (DM) (1994) (0)
Effect of Phenobarbitone on Plasma Lipids, Lipoproteins and Enzyme Induction in Healthy Young Subjects (1976) (0)
The relationship of beta-cell function with age: effect of population migration (2005) (0)
What should be the goal of cholesterol-lowering treatment? A quantitative evaluation dispelling guideline myths (2022) (0)
Proceedings: Bile cholesterol saturation varies during the menstrual cycle. (1976) (0)
Specific lipid lowering therapy in the management of diabetes. (1991) (0)
National and international recommendations for the management of hyperlipidaemia (2007) (0)
Predictors of Overall/Cardiovascular Mortality in Patients With Early Inflammatory (2012) (0)
Hypercholesterolaemia: what to do when first‐line treatment fails (2012) (0)
Diseases Related to Ergonomic and Mechanical Factors (2010) (0)
Inorganic dusts: general aspects (2010) (0)
Other Systemic Effects (2010) (0)
Lipid treatment strategies for metabolic syndrome in established cardiovascular disease: a consensus guideline (2006) (0)
Response letter to the editor. (2015) (0)
Lipoprotein Lipase Activity in the Pathological Metabolism of Lipoproteins (1994) (0)
SERUM PARAOXONASE: ITS CLINICAL SIGNIFICANCE (2006) (0)
P164 PROTECTION AGAINST NEPHROPATHY IN TYPE 2 DIABETES WITH ATORVASTATIN: RELATIONSHIP BETWEEN LIPOPROTEIN PHOSPHOLIPASE A2 AND ADIPONECTIN AND RENAL FUNCTION (2010) (0)
Lipoprotein (a), oxidised-LDL, sRAGE and carotid atherosclerosis in patients with systemic lupus erythematosus (2011) (0)
Paraoxonase 1 and atherosclerosis (2023) (0)
Divergent Changes In Lipoprotein(A) And Oxidised Phospholipids Following Metabolic Surgery (2019) (0)
The role of lipids in the development of the atherosclerotic plaque (2001) (0)
OP0118 Predictors of overall/cardiovascular mortality in patients with early inflammatory polyarthritis; the lipid-paradox? (2013) (0)
A study of the effects of bezafibrate on lipids, lipoproteins, fibrinogen and glycaemic control in hyperlipidaemic insulin-dependent diabetes mellitus (IDDM) (1990) (0)
Is pre beta high density lipoprotein (HDL) the preferred substrate for lecithin: cholesterol acyltransferase (LCAT) (1989) (0)
Influence of the glucose tolerance test on pro-atherogenic modification of LDL and its relation to paraoxonase activity (2011) (0)
Circulating neopterin and monocyte chemoattractant protein-1 are responsive to statin therapy but are poor predictors of cardiovascular events in type 2 diabetes in CARDS (2009) (0)
The association between hypertriglyceridaemia (HTG) & hyperuricaemia : Experiments with fibril acid derivatives & fructose (1987) (0)
The treatment of diabetic dyslipidaemia (1999) (0)
Hydrolysis of Platelet-Activating Factor by Purified High-Density Lipoprotein Associated Paraoxonase (1995) (0)
Alcohol and Health: Social Evolution, Production and Control (2021) (0)
myocardial infarction . men with and without previous and lipoproteins in middle aged Serum apolipoproteins AI and B (2005) (0)
Human Paraoxonase/Arylesterase (Hompona) Gene Polymorphism in Ischaemic Cardiomyopathy (1997) (0)
How to estimate cardiovascular risk in practice (2009) (0)
Effect of atorvastatin and niacin/LRPT on apolipoprotein e distribution, metabolism and glycation (2015) (0)
Obesity related neuropathy is associated with HDL functionality (2018) (0)
Novel insights into potential mechanisms by which bariatric surgery reduces cardiovascular disease risk: Oral communication (2018) (0)
Effect of Antioxidant Supplementatation on the Susceptibility of Low (LDL) and High Density (HDL) Lipoproteins to Oxidation (1995) (0)
Fast Facts: Hyperlipidemia: Bringing clarity to lipid management (2021) (0)
Imaging Study Vascular Function: A Randomized, Placebo-Controlled, Magnetic Resonance Effects of High-Dose Modified-Release Nicotinic Acid on Atherosclerosis and (2009) (0)
Alterations of Reverse Cholesterol Transport in Stable Chronic Renal Impairment (1995) (0)
Biochemical tests for acute pancreatitis. (1986) (0)
Hydrolysis of platelet-activating factor by purified HDL-associated paraoxonase (1994) (0)
Mathematical modelling of the most effective goal of cholesterol-lowering treatment in primary prevention (2022) (0)
A meta-analysis of the effect of intensive cholesterol reduction on numbers needed to treat to prevent cardiovascular events in 75439 participants in 10 randomised controlled clinical trials. (2017) (0)
Lipoprotein (a) in the Interstitial Fluid and Serum of Patients with Chronic Renal Failure and Matched Controls (1996) (0)
Estimated 10-year cardiovascular risk in a British population: Results of a national screening project (2007) (0)
History and Development of Occupational Medicine (2010) (0)
Changes in reverse cholesterol transport (RCT) in nephrotic syndrome (1995) (0)
Fats and the British diet (1991) (0)
The effect of hepatic fat on lipolysis and insulin resistance (2011) (0)
GuidelinesESC/EAS Guidelines for the Management of Dyslipidaemias (2013) (0)
Fetal and maternal lipoproteins in uncomplicated and diabetic third trimester pregnancy (1996) (0)
Serum lipoproteins among Indian Gujaratis living in the UK compared to contemporaries in India (2002) (0)
Diagnosis of Occupational Disease (2010) (0)
Impact of migration on circulating adipocytokines in an Asian Indian population (2006) (0)
Raised Creatinine protein in Indian migrant women living in the UK and its relation to CHD risk factors (2001) (0)
Reverse cholesterol transport and other functions of high density lipoprotein are enhanced after bariatric surgery (2017) (0)
The first recorded heterozygote for familial hypercholesterolemia. (2009) (0)
Comparison of factors associated with total sRAGE and esRAGE in patients with type 2 diabetes (2010) (0)
Drugs Affecting Lipid Metabolism: A.L. Catapano, A.M. Gotto, L.C. Smith, R. Paoletti (Editors) Kluwer Academic Publishers, Dordrecht, 1993; 521 pp.; stg£107.00, US$159.00, Dfl 270.00; ISBN 0-7923-2232-0 (1994) (0)
Background—It is unclear whether levels of high-density lipoprotein cholesterol (HDL-C) or apolipoprotein A-I (apoA-I) remain inversely associated with cardiovascular risk among patients who achieve very low levels of low-density lipoprotein cholesterol on statin therapy. It is also unknown whether (2013) (0)
Effect on lipoproteins of different progestogens in combination with conjugated oestrogen as hormone replacement therapy (2002) (0)
2P-0433 Rates of diabetes and macrovascular risk factors in Indian migrants in Britain compared with contemporaries in villages of origin in India (2003) (0)
Early life determinants of serum adiponectin, HDL-cholesterol and insulins in infants and children of South Asian and White European origin; the Manchester Children?s Growth and Vascular Health study (2011) (0)
Abstract 823: C-reactive Protein and Amyloid A as Predictors of Cardiovascular Events in Type 2 Diabetes in CARDS (2009) (0)
Other fibrous mineral dusts (2010) (0)
Variation And Distribution Of Apolipoprotein E And Its Glycation In Plasma Of Type 2 Diabetes (2019) (0)
University of Dundee Effect of atorvastatin on glycaemia progression in patients with diabetes (2015) (0)
Genome wide scan of soluble RAGE levels in a diabetic population reveals a novel associated variant in RAGE-HLA-DQA2 region (2011) (0)
Paraoxonase (PON1) & coronary heart disease (2000) (0)
The secretion of apolipoprotein B containing lipoproteins by hep G2 cells: Effects of glucagon and insulin (1991) (0)
Plasma lipoproteins and markers of cholestasis in patients with psoriasis treated with low-dose cyclosporin (1994) (0)
The clinical implications of GAD antibody positivity in older patients with established non-insulin requiring diabetes (2008) (0)
Serum Lipoprotein (a) Levels in Patients with Familial Hypercholesterolaemia, Their Relatives and Control Populations (Introduced by Mrs Member:- Dr.P.N. Durrington) (1990) (0)
ANY QUESTIONS (1996) (0)
The effect of atorvastatin therapy on tumour necrosis factor-α and vascular adhesion molecules in patients with type 2 diabetes mellitus with no prior history of coronary heart disease (2011) (0)
Changes in function and structure of high-density lipoprotein in obese patients compared with healthy controls (2011) (0)
Inorganic Dust Diseases (2010) (0)
Apolipoprotein e phenotype polymorphism & lipoproteins in insulin treated diabetes mellitus (1987) (0)
Effect of extended release niacin on HDL functionality, apoB lipoprotein metabolism and mediators of vascular inflammation in statin treated patients (2014) (0)
Changes in serum lipids, lipoproteins, cholesterol esterification (LCAT) and cholesteryl ester transfer (CET) activity during weight reduction in obese subjects (1995) (0)
P335 SMALL-DENSE LDL IS A BETTER DETERMINANT OF PLASMA GLYCATED APOLIPOPROTEIN B THAN GLYCAEMIA IN METABOLIC SYNDROME AND TYPE 2 DIABETIC PATIENTS (2010) (0)
Lipids in cardiovascular disease. (1993) (0)
Preventive Cardiology: Pocketbook (1993) (0)
Lipoprotein (a) in familial hypercholesterolaemia (2022) (0)
Circulating sRAGE as a Predictor of Acute Cardiovascular Events in Type 2 Diabetes in CARDS (2009) (0)
HDL antioxidant function is impaired and adipose tissue inflammation is pronounced in obese patients with increasing severity of sleep apnea (2014) (0)
Reply to: "Comments on 'Optimising treatment of hyperlipidaemia: Quantitative evaluation of UK, USA and European guidelines taking account of both LDL cholesterol levels and cardiovascular disease risk' ". (2019) (0)
Alterations in the activity of reverse cholesterol transport: a contributing factor to the hyperlipidemia of nephrotic syndrome? (1994) (0)
Irish nephrological society (1994) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Paul N. Durrington?

Paul N. Durrington is affiliated with the following schools: